Immunoclin Overview

  • Founded
  • 2000
Founded
  • Status
  • Out of Business
  • Employees
  • 2
Employees
  • Latest Deal Type
  • Out of Business
  • Financing Rounds
  • 2
  • Investments
  • 1

Immunoclin General Information

Description

Operator of a healthcare company based in Washington DC, United States. The company specializes in developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple human conditions.

Contact Information

Formerly Known As
Pharma Investing News
Ownership Status
Out of Business
Financing Status
Corporation
Primary Industry
Drug Discovery
Primary Office
  • 1420 North Street
  • Suite 102
  • Washington DC, 20005
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunoclin Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immunoclin‘s full profile, request access.

Request a free trial

Immunoclin Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunoclin Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000000 0 18-Dec-2013 000000000000000000 Media and Information Services (B2B) 0000000 0000 00.0
To view Immunoclin’s complete acquisitions history, request access »

Immunoclin Subsidiaries (1)

Company Name Industry Location Founded
000000 000000000 0 Media and Information Services (B2B) Beverly Hills, CA 0000
To view Immunoclin’s complete subsidiaries history, request access »